Literature DB >> 8874157

Stereoselectivity of Ca2+ channel block by dihydropyridines: no modulation by the voltage protocol.

R Handrock1, S Herzig.   

Abstract

The L-type Ca2+ current inhibition by the enantiomers of the dihydropyridine niguldipine was investigated at various holding potentials (-40 to -120 mV) and stimulus frequencies (0.1-1 Hz), using guinea-pig ventricular myocytes. Block of whole-cell current is both voltage- and concentration-dependent. (S)-Niguldipine is more potent than its (R)-enantiomer. However, the extent of enantioselectivity is rather small (< or = x 4.4). Importantly, this value does not increase when stimulus conditions favour the inactivated channel state, although this leads to more potent block. This is in contrast to our expectation based on modulated receptor hypothesis, and to the high enantioselectivity of niguldipine binding found in guinea-pig heart membranes (x 40). We conclude that the common modulated receptor hypothesis had to be refined to explain the effects of niguldipine enantiomers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8874157     DOI: 10.1016/0014-2999(96)00465-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Dihydropyridine enantiomers block recombinant L-type Ca2+ channels by two different mechanisms.

Authors:  R Handrock; R Rao-Schymanski; N Klugbauer; F Hofmann; S Herzig
Journal:  J Physiol       Date:  1999-11-15       Impact factor: 5.182

2.  Zebrafish as a model for cardiovascular development and disease.

Authors:  Catherine T Nguyen; Qing Lu; Yibin Wang; Jau-Nian Chen
Journal:  Drug Discov Today Dis Models       Date:  2008

3.  Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.

Authors:  Edward Perez-Reyes; Amy L Van Deusen; Iuliia Vitko
Journal:  J Pharmacol Exp Ther       Date:  2008-10-30       Impact factor: 4.030

4.  Molecular mechanisms of vasoselectivity of the 1,4-dihydropyridine lercanidipine.

Authors:  Susanne Wirtz; Stefan Herzig
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.